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Extra-hepatic Feeding Arteries of Hepatocellular Carcinoma: An Investigation Based on 
Intra-Arterial CT Aortography Images using an Angio-MDCT System. 
 
Abstract  
Objectives: We investigated the frequencies and factors associated with the presence of 
extra-hepatic feeding arteries (EHFAs) of hepatocellular carcinoma (HCC) using 
intra-arterial CT aortography images. 
Methods: A total of 173 patients with HCC who underwent transarterial 
chemoembolization (TACE) in our institution between January 2013 and March 2015 
were enrolled. The types of EHFAs were evaluated by CT aortography images using an 
apparatus that combines multidetector-row computed tomography and angiography 
system. In addition, factors associated with the presence of EHFAs were determined.  
Results: EHFAs were present in 22 (12.7%) patients with HCC. EHFAs most frequently 
branched from the right inferior phrenic artery (n=19), while others branched from the 
right adrenal artery (n=2), right renal artery (n=2), right internal thoracic artery (n=2), 
branches of the superior mesenteric artery (n=1), and an unknown artery from the aorta 
(n=1). Factors significantly associated with the presence of EHFAs in multivariate 
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analysis were tumor size ≥ 30 mm (hazard ratio (HR), 5.233 [95% confidence interval 
(CI), 1.507–17.413]; p = 0.009) and number of prior TACE treatments ≥ 3 (HR, 6.847 
[95% CI, 1.928–24.311]; p = 0.003).  
Conclusions: EHFAs of HCC were assessed with CT aortography images. Repeat 
TACE treatments and large tumor size were risk factors for the presence of EHFAs. 
 
Highlights 
 Multi detector-raw computed tomography angiography can assess extrahepatic 
feeding of hepatocellular carcinoma entirely. 
 Multi detector-raw computed tomography can assessed extrahepatic feeding of 
hepatocellular carcinoma difficult to find by angiography. 
 Factors significantly associated with the presence of EHFAs in multivariate 
analysis were tumor size ≥ 30 mm and number of prior transarterial 
chemoembolization treatments ≥ 3.  
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TACE, transcatheter arterial chemoembolization; HCC, hepatocellular carcinoma; 
EHCAs, extra-hepatic collateral feeding arteries; MDCT, multidetector-row computed 
tomography; angio-MDCT, apparatus that combines multidetector-row computed 
tomography and angiography system; 3D, 3-dimensional; HR, hazard ratio; CI, 
confidence interval; DSA, digital subtraction angiography; CT, computed tomography; 
CTHA, computed tomography during hepatic arteriography; CTAo, computed 
tomography during aortography; HCV, hepatitis C virus; HBV, hepatitis B virus; AFP, 
α-fetoprotein; AFP-L3, Lens culinaris agglutinin-reactive α-fetoprotein, DCP; 
des-γ-carboxy prothrombin; EASL, European Association For The Study Of The Liver; 
US, ultrasonography; MRI, magnetic resonance imaging; ROC, receiver operating 
characteristic curve; LAT, locoregional ablative therapy; HAIC, hepatic arterial infusion 
chemotherapy; RIPA, right inferior phrenic artery; RARA, right adrenal artery; SMA, 







































































Hepatocellular carcinoma (HCC) is currently the third and fifth most common cause of 
cancer-related deaths in men and women in Japan, respectively [1]. Transcatheter 
arterial chemoembolization (TACE) is a mainstay of treatment for unresectable HCC, 
especially in the intermediate stage [2, 3]. In addition, it has been reported that TACE 
improves survival rates in HCC patients [4, 5]. 
Extra-hepatic feeding arteries (EHFAs) sometimes contribute to the blood supply of 
HCC and complicate the TACE procedure. Failure to detect EHFAs reduce treatment 
efficacy. It is therefore important to have sufficient knowledge regarding EHFAs in 
HCC patients, and to assess these collateral pathways while performing TACE. 
Previous studies have almost always evaluated EHFAs of HCC using selective 
angiography [6, 7], but this method is not sufficiently sensitive. We recently reported the 
utility of a newly developed apparatus that combines multidetector-row computed 
tomography (MDCT) and an angiography system (angio-MDCT) [8]. It is possible to 
perform intra-arterial CT aortography (CTAo) using angio-MDCT, and the images 
obtained by CTAo include comprehensive information on all arteries in the scan range. 
Therefore, in contrast to the conventional method, CTAo allows us to evaluate all 




































































The aim of the present study was to investigate the frequencies and factors associated 
with the presence of EHFAs in HCC patients using intra-arterial CTAo images derived 
with the angio-MDCT system. 
 
Materials and methods 
Patient selection and analysis  
 Between January 2013 and March 2015, a total of 302 patients with HCC underwent 
TACE using the angio-MDCT system at the Department of Gastroenterology of Ogaki 
Municipal Hospital, Japan. When individuals underwent more than one TACE 
procedure during this period, we used patient data at the first time of TACE. Therefore, 
173 HCC patients were eventually included in this study.  
The diagnosis of HCC was confirmed based on the European Association for the Study 
of The Liver (EASL) guidelines [9]. All laboratory data were measured at the time of 
HCC diagnosis, including blood tests for tumor markers of HCC (α-fetoprotein [AFP], 
Lens culinaris agglutinin-reactive α-fetoprotein [AFP-L3], and des-γ-carboxy 
prothrombin [DCP]). The study protocol was approved by the institutional review board 






































































Construction of 3-dimensional vascular images using CT aortography protocol  
 An angio-MDCT system consisting of 64-MDCT (Aquilion CX; Toshiba Medical 
Systems) and angiography units with digital subtraction angiography (DSA) equipment 
and a C-arm (Infinix Celeve-I INFX 8000C; Toshiba Medical Systems) was introduced 
at our institution in December 2012. All CT images in the present study were obtained 
using this system. 
 The entire treatment procedure was performed under local anesthesia with lidocaine. 
After the placement of a 3-5 French sheath via the femoral artery, the tip of a pigtail 
catheter was advanced into the aorta to the level of the carina. CTAo was performed 
with the injection of 90 mL of nonionic contrast medium at a 1:2 dilution (Iopamiron 
300; Bayer Yakuhin, Osaka, Japan) at a rate of 9 mL/s. CT images were obtained 8 s 
after the initiation of contrast medium injection, from the diaphragm to the kidney at 
120 kVp with automatic tube current modulation, 0.838 pitch, 0.5 s per rotation, and a 
64 × 0.5 mm data acquisition system. After data acquisition, axial images were 
reconstructed with a slice thickness of 1.0 mm and a slice interval of 0.5 mm. An 
experienced radiologic technologist identified target feeding arteries based on the axial 




































































a workstation (Synapse Vincent; Fujifilm Medical, Tokyo, Japan). A 3D vascular image 
was constructed based on our previous report [8].  
 
Identification of EHFAs of HCC  
 Prior to TACE, CTAo was performed to obtain a detailed understanding of the 
vascular anatomy and to detect EHFAs. Subsequently, to allow for accurate evaluation 
of the spread of HCC in the liver and the vasculature, all patients underwent a baseline 
examination with DSA from the common or proper hepatic artery, CT during arterial 
portography, and CT during hepatic arteriography (CTHA) [10-12].  
 After the baseline examinations, CTAo images were compared with CTHA images. 
Areas of the target tumor showing enhancement on CTAo but not on CTHA indicated 
the existence of EHFAs. In these cases, we carefully analyzed the CTAo images, 
especially the arteries near the target tumor, to identify EHFAs. The EHFAs were color 
coded on the 3D vascular images to clearly identify them for the operator.  
 
Statistical analysis 
The SPSS software package, version 15.0 (SPSS Inc, Chicago, IL, USA), was used for 




































































the number of prior TACE treatments, which was expressed as a mean (range). 
Categorical variables were expressed as numbers (percentages). Continuous variables 
were compared using the Mann–Whitney U test, and categorical variables were 
compared using the chi-square test to assess the presence of EHFAs based on 
univariable analysis. Logistic regression analysis was used to estimate the odds ratio in 
the presence of EHFAs with the following parameters in all patients: AFP (≤ 20.0 
ng/mL or > 20.0 ng/mL), AFP-L3 (≤ 10.0 % or > 10.0 %), DCP (≤ 40 mAU/ml or > 40 
mAU/ml), tumor size (< 30 mm or ≥ 30 mm), tumor location in liver (surface or not 
surface), portal thrombus (absent or present), and the number of prior TACE treatments 
(< 3 or ≥ 3). We defined the tumor location as “surface” if at least one tumor was 
situated in the liver periphery. Logistic regression analysis was used to estimate the 
odds ratio in the presence of EHFAs with the following parameters among the subgroup 
of patients with HCC located on the liver surface (n=133): AFP (≤ 20.0 ng/mL or > 20.0 
ng/mL), DCP (≤ 40 mAU/ml or > 40 mAU/ml), tumor size (< 30 mm or ≥ 30 mm) and 
the number of prior TACE treatments (< 3 or ≥ 3). We used the lower or upper limit of 
the reference values at our institution as cut-off values for laboratory data, as 
appropriate, and determined the cut-off values for the tumor number and number of 




































































curves (ROCs) (data not shown). Statistical significance was defined as p < 0.05.  
 
Results 
Patient characteristics  
The clinical backgrounds of the study patients are shown in Table 1. The median age 
was 73 years, and there was a predominance of men (70.5%). One hundred forty-six 
patients had hepatitis related to hepatitis B or C virus (84.4%). With regard to liver 
function as categorized by Child-Pugh class, 116 (66.5%) patients were class A, 54 
(31.8%) were class B, and 3 (1.7%) were class C. Regarding tumor factors, the median 
tumor size was 22 mm. There were 120 (69.2%) patients with multiple tumors and 11 
(6.4%) with portal thrombi. Eighty-six of 173 patients (49.7%) had previously 
undergone TACE, and the mean number of prior TACE treatments was one (0-10).  
 
Frequency and types of EHFAs of HCC patients. 
Twenty-two patients with HCC had EHFAs (12.7%). Table 2 shows the types of 
EHFAs; the majority involved the right inferior phrenic artery (RIPA) (n=19). However, 
in one case the EHFA was an unknown artery supplied directly by the aorta (Fig. 1). 




































































remaining 5 patients with no history of TACE (RIPA only, n=4; RIPA and right adrenal 
artery, n=1), tumors were very large (median 109 mm, range 39-120), and 2 cases had 
ruptured tumors fed by the hepatic artery and inferior phrenic artery (IPA).   
 
Factors associated with the presence of EHFAs in the entire patient population 
Factors associated with the presence of EHFAs by univariate analysis were listed in 
Table 3. The following associations were statistically significant: AFP, AFP-L3, DCP, 
tumor size, tumor location in the liver, portal thrombus, history of TACE, and the 
number of prior TACE treatments. Of these, the factors that were significantly 
associated with the presence of EHFAs in multivariate analysis were tumor size ≥ 30 
mm (hazard ratio (HR), 5.233 [95% confidence interval (CI), 1.507–17.413]; p = 0.009) 
and number of prior TACE treatments ≥ 3 (HR, 6.847 [95% CI, 1.928–24.311]; p = 
0.003) (Table 4).  
 
Factors associated with the presence of EHFAs among patients with HCC located on 
the liver surface 
We subsequently investigated the subgroup of patients with HCC located on the liver 




































































on the liver surface in the present study. In this group, univariate analysis showed that 
the presence of EHFAs was significantly associated with the following factors: AFP, 
DCP, tumor size, history of TACE and number of prior TACE treatments. Of these, 
multivariate analysis identified the following as significant: tumor size ≥ 30 mm (HR, 
6.259 [95% CI, 1.956–20.026]; p = 0.002) and number of prior TACE treatments ≥ 3 
(HR, 10.345 [95% CI, 3.010–35.557]; p < 0.001) (Supplemental Tables 1 and 2). 
 
Discussion 
Previous studies noted the effectiveness of TACE with angio-CT, a technique that 
combines an angiographic imager with CT [13, 14]. Angio-CT is a useful modality for 
investigating hemodynamics and the process of differentiation from early to advanced 
HCC [15]. It has also improved the efficacy of TACE, prolonging survival rates in HCC 
patients [16]. In addition, CTAo images using the angio-MDCT system have enabled 
the rapid and accurate identification and subsequent catheterization of feeding arteries 
of HCC [8, 17]. In the present study, we assessed the frequencies and types of EHFAs in 
HCC patients based on CTAo images derived using the angio-CT system.  
It is known that various types of EHFAs develop and supply HCC tumors. Previous 




































































omental arteries as EHFAs supplying HCC [7, 18]. In this study, 12.7% of patients had 
EHFAs. Most involved the IPA, which has previously been identified as the most 
common source of EHFAs in patients with HCC [6, 19]. In one patient the EHFA was 
an unknown artery that branched directly from the aorta.  
The conventional method of identifying EHFAs requires first expecting feeders based 
on DSA and CT imaging, then selecting each suspected artery and confirming whether 
it is an EHFA using DSA or contrast-enhanced CT. However, this method is 
time-consuming and may increase exposure to X-rays and contrast medium.  
In contrast, CTAo using angio-MDCT can comprehensively scan and analyze a large 
area in a very short period of time. It reduces the physical and mental stress of operators 
and is more sensitive than the conventional method, making it possible to easily detect 
rare arteries like the unknown artery identified in the present study.  
Arteries in CTAo images have high contrast compared with intra-venous CT 
angiography. In patients who underwent TACE or dynamic CT examination at our 
institution, images of the aorta derived by CTAo demonstrated double the CT number 
of those obtained with intra-venous CT angiography, thus increasing noise tolerance, 
and CTAo required a smaller volume of contrast medium (data not shown). Furthermore, 




































































intra-venous CT angiography. 
When we used multivariate analysis to determine the factors associated with the 
presence of EHFAs, tumor size ≥ 30 mm and number of prior TACE treatments ≥ 3 
were selected as independent risk factors. Feeders of large HCCs tend to be extrahepatic 
arteries [20], and the presence of EHFAs should be a particular concern in such cases 
even if TACE is being performed for the first time (Fig. 2). On the other hand, repeated 
TACE induces hepatic arterial damage and increases the occurrence of EHFAs [6, 21]. 
The TACE procedure requires that the patient have satisfactory liver function. The 
percentage of HCC patients with Child-Pugh class A liver function is increasing in 
Japan because of treatment of viral hepatitis and the development of surveillance 
systems for HCC [22]. For these reasons, the number of HCC patients with good 
remnant liver function is expected to rise in the near future, and the opportunity for 
repeat TACE procedures will increase. Hence, it is important to be familiar with EHFAs 
of HCC and the appropriate TACE techniques to use in their presence.  
Previous studies have reported a relationship between the presence of EHFAs and the 
location of HCC [6, 23]. In the present study, however, tumor location was a significant 
risk factor by univariable but not multivariable analysis. We therefore assessed the 




































































prior TACE treatments were identified as significant risk factors by logistic regression 
analysis, as was the case in the entire patient population. Close attention should be paid 
to the possible presence of EHFAs in advanced HCC patients with a history of repeat 
TACE, regardless of tumor location.  
In the present study there were limitations in the examination of EHFAs by CTAo. 
Because CTAo was performed using contrast administered at the aorta, our assessment 
of the internal thoracic artery was limited. Although one patient had an EHFA involving 
the internal thoracic artery, we identified this artery via axial CT imaging.  
 In conclusion, repeat TACE procedures and tumor size were independent risk factors 
for the presence of EHFAs. The IPA was the most common EHFA, and therefore attention 
should be paid to this artery in patients with a history of repeat TACE procedures or large 
tumors. CTAo using angio-MDCT is very useful for rapid identification of other EHFAs, 
including unknown arteries. The use of CTAo images to locate EHFAs of HCC could 
provide accurate information on these unusual feeders of HCC, including their most 
common sources and any associated risk factors. Further prospective studies will be 
needed to assess whether TACE with CTAo using angio-MDCT contributes to 
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Table 1. Clinical backgrounds of study patients (n=173). 
 
Age (years) 73 (37–88) 
Sex (female / male) 51 (29.5%) / 122 (70.5%) 
Etiology (HBV / HCV / non-HBV and 
non-HCV) 
21 (12.1%) / 125 (72.3%) / 27 (15.6%) 
Alcohol abuse (negative / positive) 
*
  161 (93.1%) / 12 (6.9%) 
Child-Pugh classification (A / B / C) 116 (66.5%) / 54 (31.8%) / 3 (1.7%) 
AFP (ng/mL) 16.9 (0.3–106851) 
AFP-L3 (%) 6.0 (0–99.5) 
DCP (mAU/mL) 57 (5–50000) 
Tumor size (mm) 22 (7–120) 
Tumor number (single / multiple) 53 (30.8%) / 120 (69.2%)  
Portal thrombus (absent / present) 162 (93.6%) / 11 (6.4%) 
Primary / Recurrence 35 (20.2%) / 138 (79.8%) 
Initial treatment (n=138)  
Hepatectomy / LAT
**
 / TACE / HAIC  52 (37.7%) / 47 (34.1%) / 36 (26.1%) / 
3 (2.1%) 
Replace ( + / − ) 29 (16.8%) / 144 (83.2%) 
History of TACE ( + / − ) 86 (49.7%) / 87 (50.3%) 










HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, α-fetoprotein; AFP-L3, Lens culinaris 
agglutinin-reactive α-fetoprotein; DCP, des-γ-carboxy prothrombin; LAT, locoregional ablative 
therapy; TACE, transcatheter arterial chemoembolization; HAIC, hepatic arterial infusion 
chemotherapy. 
* Alcohol abuse was defined as intake ≥ 60 g/day.  







































































RIPA only  16 
RIPA + RARA 1 
RIPA + branch of SMA 1 
RIPA + RRA + RITA 1 
RRA 1 
RARA 1 
unknown artery (from aorta) 1 
 
RIPA, right inferior phrenic artery; RARA, right adrenal artery; SMA, superior mesenteric 



































































Table 3. Factors associated with the presence of extra-hepatic feeding arteries based on 
univariable analysis. 
 
Factor EHFA absent (n=151) EHFA present (n=22) p value 
Age (years) 73 (37–88) 72 (42–85) 0.834 
Sex (female / male) 45 (29.8%) / 106 (70.2%) 6 (27.3%) / 16 (72.7%)  
0.808 
Etiology (HBV / HCV / 
non-HBV and non-HCV) 
17 (11.3%) / 108 (71.5%) 
/ 26 (17.2%) 
4 (18.2%) / 17  
(77.3%) / 1 (4.5%) 
0.244 
Alcohol abuse  
(negative / positive) *  
139 (92.1%) / 12 (7.9%) 0 (0%) / 22 (100%) 
0.171 
Child-Pugh classification 
( A / B / C ) 
102 (67.5%) / 46 (30.5%) 
/ 3 (2.0%) 
14 (63.6%) / 8 (36.4%) 
/ 0 (0%)  
0.706 
AFP (ng/mL) 14.6 (0.3–106851) 177.6 (6.1–19932.7) < 0.001 
AFP-L3 (%) 5.4 (0–99.5) 7.4 (0.5–84.7) 0.029 
DCP (mAU/mL) 44 (5–50000) 294.5 (15–50000) < 0.001 
Tumor size (mm) 21 (8–108) 35 (7–120) < 0.001 
Tumor number 
 (single / multiple) 
48 (31.8%) / 103 (68.2%) 5 (22.7%) / 17 (77.3%)  
0.389 
Portal thrombus  
(absent / present) 
144 (95.4%) / 7 (4.6%) 4 (18.2%) / 18 (81.8%)  
0.015 
Tumor location in liver       
( surface / not surface ) 
112 (74.2%)           
/ 39 (25.8%) 
21 (95.5%)          
/ 1 (4.5%) 
0.027 
Replace  
( + / − ) 
25 (16.6%) / 126 (83.4%) 4 (18.2%) / 18 (81.8%) 
0.849 
History of TACE  
( + / − ) 
69 (45.7%) / 82 (54.3%) 17 (77.3%) / 5 (22.7%)  
0.006 
Number of prior TACE 
treatments†  




Values are expressed as medians (range) except for the number of prior TACE treatments. 
†
mean(range).  
EHFA, extra-hepatic feeding arteries; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, 
α-fetoprotein; AFP-L3, Lens culinaris agglutinin-reactive α-fetoprotein; DCP, des-γ-carboxy 
prothrombin; TACE, transcatheter arterial chemoembolization  



































































Table 4. Factors associated with the presence of extra-hepatic feeding arteries based on 
multivariable analysis (logistic regression analysis). 
 
Factor  Odds ratio 95% CI  p value 
Tumor size (mm) < 30  1   
 ≥ 30  5.233 1.507–17.413 0.009 
Number of prior 
TACE treatments 
< 3 1   





CI, confidence interval;  






































































A case of hepatocellular carcinoma partly fed by an extrahepatic artery from the aorta 
 
80-years-old woman with hepatocellular carcinoma (HCC) partly supplied by an 
extrahepatic artery from the aorta. The confluent multinodular-type HCC is depicted as 
an enhancement on computed tomography (CT) aortography (a, red circle). CT during 
hepatic arteriography shows that only the periphery of this tumor was supplied by the 
proper hepatic artery (b, yellow arrow). The other parts of this tumor were supplied by 
the extrahepatic artery (c, enhanced CT via the feeder directly branching from the aorta; 
d, 3D vascular image). We performed digital subtraction angiography and selective 











































































A case of large hepatocellular carcinoma fed by the posterior branch of the right hepatic 
artery and the right inferior phrenic artery. 
 
79-years-old woman with a large hepatocellular carcinoma (HCC) fed by the posterior 
branch of the right hepatic artery and the right inferior phrenic artery (RIPA). This 
patient had no history of transcatheter arterial chemoembolization. This massive HCC 
enhanced heterogeneously on computed tomography (CT) aortography (a). The tumor 
enhanced on CT during hepatic arteriography (b), however the enhancement was poor 
compared with CT aortography. With a 3D vascular image constructed from CT 
aortography images, we were able to identify the RIPA as the extrahepatic feeding 
artery (c). The feeders to the HCC from the hepatic artery and the RIPA were confirmed 




Table 1. Clinical backgrounds of study patients (n=173). 
 
Age (years) 73 (37–88) 
Sex (female / male) 51 (29.5%) / 122 (70.5%) 
Etiology (HBV / HCV / non-HBV and 
non-HCV) 
21 (12.1%) / 125 (72.3%) / 27 (15.6%) 
Alcohol abuse (negative / positive) 
*
  161 (93.1%) / 12 (6.9%) 
Child-Pugh classification (A / B / C) 116 (66.5%) / 54 (31.8%) / 3 (1.7%) 
AFP (ng/mL) 16.9 (0.3–106851) 
AFP-L3 (%) 6.0 (0–99.5) 
DCP (mAU/mL) 57 (5–50000) 
Tumor size (mm) 22 (7–120) 
Tumor number (single / multiple) 53 (30.8%) / 120 (69.2%)  
Portal thrombus (absent / present) 162 (93.6%) / 11 (6.4%) 
Primary / Recurrence 35 (20.2%) / 138 (79.8%) 
Initial treatment (n=138)  
Hepatectomy / LAT
**
 / TACE / HAIC  52 (37.7%) / 47 (34.1%) / 36 (26.1%) / 
3 (2.1%) 
Replace ( + / − ) 29 (16.8%) / 144 (83.2%) 
History of TACE ( + / − ) 86 (49.7%) / 87 (50.3%) 










HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, α-fetoprotein; AFP-L3, Lens culinaris 
agglutinin-reactive α-fetoprotein; DCP, des-γ-carboxy prothrombin; LAT, locoregional ablative 
therapy; TACE, transcatheter arterial chemoembolization; HAIC, hepatic arterial infusion 
chemotherapy. 
* Alcohol abuse was defined as intake ≥ 60 g/day.  
** LAT included radiofrequency ablation and ethanol injection.  
Table(s)
  




RIPA only  16 
RIPA + RARA 1 
RIPA + branch of SMA 1 
RIPA + RRA + RITA 1 
RRA 1 
RARA 1 
unknown artery (from aorta) 1 
 
RIPA, right inferior phrenic artery; RARA, right adrenal artery; SMA, superior mesenteric 
artery; RRA, right renal artery; RITA, right internal thoracic artery. 
  
Table 3. Factors associated with the presence of extra-hepatic feeding arteries based on 
univariable analysis. 
 
Factor EHFA absent (n=151) EHFA present (n=22) p value 
Age (years) 73 (37–88) 72 (42–85) 0.834 
Sex (female / male) 45 (29.8%) / 106 (70.2%) 6 (27.3%) / 16 (72.7%)  
0.808 
Etiology (HBV / HCV / 
non-HBV and non-HCV) 
17 (11.3%) / 108 (71.5%) 
/ 26 (17.2%) 
4 (18.2%) / 17  
(77.3%) / 1 (4.5%) 
0.244 
Alcohol abuse  
(negative / positive) *  
139 (92.1%) / 12 (7.9%) 0 (0%) / 22 (100%) 
0.171 
Child-Pugh classification 
( A / B / C ) 
102 (67.5%) / 46 (30.5%) 
/ 3 (2.0%) 
14 (63.6%) / 8 (36.4%) 
/ 0 (0%)  
0.706 
AFP (ng/mL) 14.6 (0.3–106851) 177.6 (6.1–19932.7) < 0.001 
AFP-L3 (%) 5.4 (0–99.5) 7.4 (0.5–84.7) 0.029 
DCP (mAU/mL) 44 (5–50000) 294.5 (15–50000) < 0.001 
Tumor size (mm) 21 (8–108) 35 (7–120) < 0.001 
Tumor number 
 (single / multiple) 
48 (31.8%) / 103 (68.2%) 5 (22.7%) / 17 (77.3%)  
0.389 
Portal thrombus  
(absent / present) 
144 (95.4%) / 7 (4.6%) 4 (18.2%) / 18 (81.8%)  
0.015 
Tumor location in liver       
( surface / not surface ) 
112 (74.2%)           
/ 39 (25.8%) 
21 (95.5%)          
/ 1 (4.5%) 
0.027 
Replace  
( + / − ) 
25 (16.6%) / 126 (83.4%) 4 (18.2%) / 18 (81.8%) 
0.849 
History of TACE  
( + / − ) 
69 (45.7%) / 82 (54.3%) 17 (77.3%) / 5 (22.7%)  
0.006 
Number of prior TACE 
treatments†  




Values are expressed as medians (range) except for the number of prior TACE treatments. 
†
mean(range).  
EHFA, extra-hepatic feeding arteries; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, 
α-fetoprotein; AFP-L3, Lens culinaris agglutinin-reactive α-fetoprotein; DCP, des-γ-carboxy 
prothrombin; TACE, transcatheter arterial chemoembolization  
* Alcohol abuse was defined as intake ≥ 60 g/day. 
  
Table 4. Factors associated with the presence of extra-hepatic feeding arteries based on 
multivariable analysis (logistic regression analysis). 
 
Factor  Odds ratio 95% CI  p value 
Tumor size (mm) < 30  1   
 ≥ 30  5.233 1.507–17.413 0.009 
Number of prior 
TACE treatments 
< 3 1   




CI, confidence interval;  
TACE, transcatheter arterial chemoembolization   
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